Summary
Highlights
Dr. Marta Perez welcomes viewers to her channel, focusing on genetic screening of the fetus. She explains "aneuploidy" as an incorrect number of chromosomes, with Trisomy 21 (Down Syndrome) being the most common, and emphasizes the video's informational purpose, encouraging viewers to consult their OBGYN or a genetic counselor for personalized advice.
The video clarifies the difference between screening tests (detecting risk without invasive testing) and diagnostic tests (providing definitive answers through methods like chorionic villus sampling (CVS) or amniocentesis). It highlights that screening tests are not perfect, involving concepts like sensitivity, specificity, false positives, and false negatives. A positive screening test should always be followed by a diagnostic test.
Screening for aneuploidy is offered because many find this information helpful for pregnancy planning. The risk of chromosomal anomalies increases with advancing maternal age due to the egg production process becoming less reliable over time. For example, the risk of Trisomy 21 significantly increases from age 20 to 40.
Cell-Free DNA is a blood test that can be done as early as 9-10 weeks. Its advantages include revealing fetal sex and having a high detection rate (around 99% for Trisomy 21) with a low false-positive rate. However, cons include potential lack of insurance coverage for younger individuals, and inability to be used in certain cases like organ transplant recipients or vanishing twins.
First Trimester Screening combines a blood test with an ultrasound (nuchal translucency) and detects 82-87% of Trisomy 21 cases. It's typically insurance-covered and can screen for non-genetic issues like heart or neurological problems. A Quad Screen is a second-trimester blood test, providing an option for later screening, but has a lower detection rate (81%).
It's generally not recommended to undergo multiple screening tests consecutively, especially if cfDNA is included, as it can lead to confusion. While cfDNA was initially for high-risk groups, it's now offered more broadly, with costs potentially varying based on insurance. For IVF patients who underwent pre-implantation genetic testing (PGT), genetic screening in pregnancy is still recommended due to the evolving nature of genetic technology.
Genetic screening is not mandatory, but the information gathered can be crucial for families to prepare for potential medical needs, financial planning, and support systems for a child with a chromosomal anomaly. It's important to note that an anatomy scan alone is not sufficient to rule out chromosomal issues, as only 27% of Trisomy 21 cases show structural anomalies on ultrasound.
Screening for twins is more complex. Fraternal twins have twice the risk of aneuploidy compared to identical twins. While some cfDNA companies market to twins with claimed good detection rates, robust research is limited. Nuchal translucency is generally reliable, and diagnostic testing remains an option for definitive results.
The video addresses concerns about cfDNA screening for rare genetic problems, where the risk of false positives increases due to lower disease prevalence. It stresses the need for cautious counseling and understanding of statistics. Limitations of cfDNA include maternal weight (over 250 pounds can lead to a lower fetal fraction and 'no-call' results) and situations like solid organ transplants or vanishing twins, which can affect test accuracy.
Dr. Perez concludes by welcoming more questions on aneuploidy screening, acknowledging the complexity of the topic. She aims to provide foundational knowledge to empower patients before their first trimester OBGYN visits, fostering informed discussions about individual situations. She encourages viewers to subscribe for more informative and engaging content.